Xanomeline

Drugs of the Future

Volumn 21, Issue 9, 1996, Pages 911-916

  Graul, A ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

MUSCARINIC AGENT; MUSCARINIC M1 RECEPTOR; NOOTROPIC AGENT; UNCLASSIFIED DRUG; XANOMELINE;

ALZHEIMER DISEASE; BLADDER; BRAIN; DRUG DETERMINATION; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; DYSPEPSIA; GASTROINTESTINAL DISEASE; GUINEA PIG; HEART; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; ILEUM; MONKEY; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; RABBIT; RAT; SCHIZOPHRENIA; SHORT SURVEY; SUBCUTANEOUS DRUG ADMINISTRATION; SYNCOPE; VAS DEFERENS; VOMITING;

EID: 0029800757     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1996.021.09.372353     Document Type: Short Survey

References (70)

1. 1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines. J Med Chem 1992, 35: 2274-83.
2. Sauerberg, P., Olesen, P.H., Mich, C.H. (Novo Nordisk A/S). Heterocyclic cpds. and their preparation and use. EP 687265, WO 9420495.
3. Sauerberg, P., Olesen, P.H. (Novo Nordisk A/S). Piperidine cpds. and their preparation and use. EP 384288, US 5260311, US 5264444, US 5284859, US 5328925.
4. Osborne, L.M., Shipley, L.A., Treppendahl, S., Petersen, T.G. (Novo Nordisk A/S). Heterocyclic chemistry. WO 9429303.
5. Perry, E.K. The cholinergic hypothesis - Ten years on. Brit Med Bull 1986, 42: 63-9.
6. Sims, N.R., Bowen, D.M., Smith, C.C.T., Neary, D., Thomas, D.J., Davison, A.N. Presynaptic cholinergic dysfunctions in patients with dementia. J Neurochem 1983, 40: 503-9.
7. Perry, E.K. Acetylcholine and Alzheimer's disease. Brit J Psychiatry 1988, 152: 737-40.
8. Prous, J.R. Cognition-enhancing drugs. In: The Year's Drug News - Therapeutic Targets. 1995 Edition, p. 91.
9. 1 pharmacophore. J Med Chem 1992, 35: 4011-9.
10. 1 selective muscarinic agonist hexyloxy-TZTP. Bioorg Med Chem Lett 1992, 2: 809-14.
11. 1 selective muscarinic receptor agonist xanomeline. Bioorg Med Chem Lett 1994, 4: 2205-10.
12. Ngur, D., Roknich, S., Mitch, C.H., Quimby, S.J., Ward, J.S., Merritt, L., Sauerberg, P., Messer, W.S. Jr., Hoss, W. Steric and electronic requirements for muscarinic receptor-stimulated phosphoinositide turnover in the CNS in a series of arecoline bioisosteres. Biochem Biophys Res Commun 1992, 187: 1389-94.
13. 1 receptors. J Pharmacol Exp Ther 1994, 269: 271-81.
14. 1 muscarinic agonist xanomeline (LY246708/NNC11-0232). J Pharmacol Exp Ther 1994, 269: 282-9.
15. 1 receptor agonist - Preclinical update. In: Alzheimer Disease. Therapeutic Strategies. Advances in Alzheimer Disease Therapy, E. Giacobini and R. Becker (Eds.), Birkhauser, Boston, 1994, 229-33.
16. Davey, P.T., East, S.Z., Rogers, D.C. Tacrine, but not RS86 or xanomeline, attenuate delay-induced deficits in the rat T-maze. J Psychopharmacol 1995, 9(3, Suppl.): Abst 49.
17. Ward, K.M., Chapin, D.S., Nowakowski, J.T., Forman, J.T., Nason, D.M., Villalobos, A., Liston, D.R. Muscarinic agonists increase hippocampal phosphatidyl inositol turnover in vivo and attenuate hemicholinium-3-induced amnesia in mice. Soc Neurosci Abst 1995, 21(1-3): Abst 773.7.
18. DeLong, A.F., Bonate, P.L., Gillespie, T., Henry, D.P., Satterwhite, J.H., Henry, D.P. Absorption, distribution, metabolism, and elimination of radiolabeled xanomeline in healthy male subjects. Neuropsychopharmacology 1994, 10(3S, Part 2): Abst P-117-14.
19. 1 agonist in healthy male subjects. Neuropsychopharmacology 1994, 10(3S, Part 2): Abst P-117-16.
20. Shipley, L.A., Cornpropst, J.D., Skaggs, T.G., Brown, T.J., Lindsay, T.J., Gillespie, T.A. Differences in the metabolism of xanomeline, a candidate drug in the treatment of Alzheimer's disease, in rat and monkey via oral and subcutaneous administration. 4th Int ISSX Meet (Aug 27-31, Seattle) 1995, Abst 271.
21. 1 agonist, LY246708, an investigational agent with potential for the treatment of Alzheimer's disease, in human plasma. J Chromatogr-Biomed Appl 1993, 613: 365-70.
22. 1 agonist, and its metabolite in human plasma. J Chromatogr B-Biomed Appl 1995, 669: 397-403.
23. Brown, T.J., Shipley, L.A. Determination of xanomeline (LY246708 tartrate), an investigational agent for the treatment of Alzheimer's disease, in rat and monkey plasma by capillary gas chromatography with nitrogen-phosphorus detection. J Chromatogr B-Biomed Appl 1995, 665: 337-44.
24. Gillespie, T.A., Lindsay, T.J., Cornpropst, J.D., Bonate, P.L., Skaggs, T.G., DeLong, A.F., Shipley, L.A. Analysis of xanomeline, a potential drug for Alzheimer's disease, by electrospray ionization tandem mass spectrometry. ACS Symp Ser 1996, 619(Biochemical and Biotechnological Applications of Electrospray Ionization Mass Spectrometry): 315-29.
25. 1 agonist in healthy elderly subjects. Neuropsychopharmacology 1994, 10(3S, Part 2): Abst P-117-17.
26. 1-specific cholinergic agonist, in patients with Alzheimer's disease. Neuropsychopharmacology 1994, 10(3S, Part 2): Abst P-117-15.
27. Sramek, J.J., Hurley, D.J., Wardle, T.S., Satterwhite, J.H., Hourani, J., Dies, F., Cutler, N.R. The safety and tolerance of xanomeline tartrate in patients with Alzheimer's disease. J Clin Pharmacol 1995, 35: 800-6.
28. 1 agonist in mild and moderate Alzheimer's disease. Eur Neuropsychopharmacol 1995, 5(3): Abst S-16-4.
29. 1-selective muscarinic agonist, on behavioral symptoms in Alzheimer's disease. 5th Int Conf Alzheimer's Dis Relat Disord (July 24-29, Osaka) 1996, Abst 182.
30. 1-selective muscarinic agonist xanomeline improves both the cognitive deficits and behavioral symptoms of patients with mild to moderate Alzheimer's disease. 5th Int Conf Alzheimer's Dis Relat Disord (July 24-29, Osaka) 1996, Abst 557.
31. 1 muscarinic agonist xanomeline improves both cognitive and behavioral deficits in Alzheimer's disease. Eur Neuropsychopharmacol 1996, 6(Suppl. 3): Abst O-20-4.
32. 1 selective cholinergic agonist. 5th Int Conf Alzheimer's Dis Relat Disord (July 24-29, Osaka) 1996, Abst 648.
33. Novo Nordisk Annual Report 1995.
34. Eli Lilly & Co. Report to Shareholders 1995.
35. Bymaster, F.P., Shannon, H.E. (Novo Nordisk A/S). Antipsychotic method. WO 9505174.
36. Greenwood, B. (Novo Nordisk A/S). A method of treating gastrointestinal motility disorders. WO 9517185.
37. 11C-TZTP derivatives for the visualization of muscarinic receptors in the human brain in vivo. 4th Int Nice/Springfield Symp Adv Alzheimer Ther (April 10-14, Nice) 1996, 72.
38. Lucas, R., Idzikowski, C. The effects of muscarinic agonist xanomeline on human sleep. Neurobiol Aging 1994, 15(Suppl. 1): Abst 432.
39. Pomara, N., Tun, H., Bernstein, S., Imbimbo, B.P. Plasma amyloid β protein (Aβ) in patients with probable Alzheimer's disease (AD): Relationship to cholinomimetic therapy. 5th Int Conf Alzheimer's Dis Relat Disord (July 24-29, Osaka) 1996, Abst 287.
40. 1 agonist, xanomeline, in mild and moderate Alzheimer's disease. IBC Conf Ther Opportunities Alzheimer's Dis - Adv Diagn Drug Dev (June 17-18, Oak Brook) 1996.
41. 1 agonist in mild and moderate Alzheimer's disease. IBC 4th Annu Alzheimer Dis: Latest Adv Understanding Treat (Oct 18-19, Waltham) 1995.
42. 1 agonist on behavior. Eur Neuropsychopharmacol 1995, 5(3): Abst SAT-5-3.
43. 1 agonist in healthy male subjects. Neurobiol Aging 1994, 15(Suppl. 1): Abst 430.
44. 1 agonist: Early clinical study. Psychopharmacol Bull 1994, 30(4): 722.
45. Cutler, N.R., Sramek, J.J., Seifert, R.D., Conrad, J.J., Wardle, T.S., Hurley, D.J., Thoren, L.M. A bridging study of xanomeline tartrate in Alzheimer's disease (AD). Biol Psychiatry 1994, 35(9): Abst 49.
46. 1-specific cholinergic agonist, in patients with Alzheimer's disease. Neurobiol Aging 1994, 15(Suppl. 1): Abst 428.
47. 1 agonist in healthy elderly subjects. Neurobiol Aging 1994, 15(Suppl. 1): Abst 429.
48. DeLong, A.F., Bonate, P.L., Gillespie, T., Henry, D.P., Satterwhite, J.H. Absorption, distribution, metabolism, and elimination of radiolabeled xanomeline in healthy male subjects. Neurobiol Aging 1994, 15(Suppl. 1): Abst 431.
49. 1 agonist: Early clinical study. 3rd Int Springfield Symp Adv Alzheimer Ther (May 11-15, Springfield) 1994, 77.
50. 1-specific cholinergic agonist, in patients with Alzheimer's disease. Clin Pharmacol Ther 1994, 55(2): Abst PII-86.
51. 1 agonist in healthy male subjects. Adv Behav Biol 1995, 44(Alzheimer's and Parkinson's Diseases): 469-73.
52. 1 agonist: Early clinical studies. In: Alzheimer Disease. Therapeutic Strategies. Advances in Alzheimer Disease Therapy, E. Giacobini and R. Becker (Eds.), Birkhauser, Boston, 1994, 234-8.
53. 1 agonist for the treatment of Alzheimer's disease. Neuropsychopharmacology 1994, 10(3S, Part 1): Abst S-206-867.
54. DeLong, A.F., Bonate, P.L., Gillespie, T., Henry, D.P., Satterwhite, J.H. Absorption, distribution, metabolism, and elimination of radiolabeled xanomeline in healthy male subjects. Adv Behav Biol 1995, 44(Alzheimer's and Parkinson's Diseases): 463-8.
55. 1-specific cholinergic agonist, in patients with Alzheimer's disease. 3rd Int Springfield Symp Adv Alzheimer Ther (May 11-15, Springfield) 1994, Abst P33.
56. DeLong, A.F., Bonate, P.L., Gillespie, T, Henry, D.P., Satterwhite, J.H. Absorption, distribution, metabolism, and elimination of radiolabeled xanomeline in healthy male subjects. 3rd Int Springfield Symp Adv Alzheimer Ther (May 11-15, Springfield) 1994, Abst P34.
57. 1 agonist in healthy elderly subjects. 3rd Int Springfield Symp Adv Alzheimer Ther (May 11-15, Springfield) 1994, Abst P35.
58. 1 agonist in healthy male subjects. 3rd Int Springfield Symp Adv Alzheimer Ther (May 11-15, Springfield) 1994, Abst P36.
59. 1 muscarinic agonist in vitro. Adv Behav Biol 1995, 44(Alzheimer's and Parkinson's Diseases): 457-61.
60. 1 muscarinic agonist in vitro. Neurobiol Aging 1994, 15(Suppl. 1): Abst 427.
61. Farde, L., Suhara, T., Halldin, C., Karlsson, P., Nybäck, H. New radioligands for PET-examination of central muscarinic receptors. Neurobiol Aging 1994, 15(Suppl. 1): Abst 433.
62. 1 muscarinic agonist in vitro. 3rd Int Springfield Symp Adv Alzheimer Ther (May 11-15, Sprinfield) 1994, Abst P38.
63. 1 agonist - Preclinical update. 3rd Int Springfield Symp Adv Alzheimer Ther (May 11-15, Springfield) 1994, 76.
64. 1 muscarinic agonist in vitro. Neuropsychopharmacology 1994, 10(3S, Part 2): Abst P-117-13.
65. Farde, L., Suhara, T., Halldin, C., Karlsson, P., Nybäck, H., Müller, L., Foged, C., Sauerberg, P., Lucas, R. New radioligands for PET-examination of central muscarinic receptors. Neuropsychopharmacology 1994, 10(3S, Part 2): Abst P-117-12.
66. 1 agonist in-vitro. Soc Neurosci Abst 1992, 18(1-2): Abst 481.7.
67. 1 agonist xanomeline potently stimulates APPs release from CHO-m1 cells. Life Sci 1995, 56(11-12): Abst 45.
68. 1 selective agonist hexyloxy-TZTP. Life Sci 1993, 52(5-6): Abst 2.
69. 1 agonist in vitro. Life Sci 1993, 52(5-6): Abst 3.
70. 1 receptor agonist for Alzheimer's disease. Eur Neuropsychopharmacol 1995, 5(3): Abst SAT-5-2.